/p>
Miles D. White, chairman and chief executive officer, Abbott
Go Red Heart Checkup
Women throughout the Bay Area can register today for a free online
heart checkup that predicts their personal risk of having a heart attack
within 10 years. To register, visit GoRedForWomen.org.
About Abbott
Abbott (NYSE: ABT) is a global, broad-based health care company devoted
to the discovery, development, manufacturing and marketing of
pharmaceuticals and medical products, including nutritionals, devices and
diagnostics. The company employs 65,000 people and markets its products in
more than 130 countries. Abbott's news releases and other information are
available on the company's Web site at http://www.abbott.com.
Related Links
Go Red for Women
[http://www.goredforwomen.org/]
Women, Heart Disease and Stroke, the American Heart Association
[http://www.americanheart.org/presenter.jhtml?identifier=4786]
American Heart Association
[http://www.americanheart.org/]
'/>"/>Page: 1 2 3 Related medicine news :1.
Abbott to Present at Merrill Lynch Healthcare Conference2.
Abbotts Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA3.
Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2007 Earnings4.
Cookie Johnson and Abbott Bring I Stand With Magic: Campaign to End Black AIDS to Los Angeles to Educate African-American Women on HIV/AIDS5.
Ugandan Children Are Among the First to Receive Abbotts Lower-Strength Aluvia (lopinavir/ritonavir) Tablet6.
The Magic Johnson Foundation and Abbott Expand Focus of Campaign to End Black AIDS to African-American Women in 20087.
FDA Advisory Committee Recommends Approval of Abbotts XIENCE(TM) V Drug Eluting Stent System8.
Abbotts Environmental Protection Initiatives Again Recognized by the State of Illinois9.
Abbott Employees Give Back to Local Communities This Holiday Season10.
AUDIO from Medialink and Abbott Labs: Easing Holiday Stress for Families of Those With Diabetes11.
Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients